Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Fiche publication
Date publication
mai 2020
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Pr GHIRINGHELLI François, Dr LIMAGNE Emeric, Dr THIBAUDIN Marion
Tous les auteurs :
Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F
Lien Pubmed
Résumé
Predictive biomarkers of response to chemotherapy plus antiangiogenic for metastatic colorectal cancer (mCRC) are lacking. The objective of this study was to test the prognostic role of splenomegaly on baseline CT scan.
Mots clés
MDSC, circulating monocytic myeloid derived suppressor cells, metastatic colorectal cancer, prognostic biomarker, splenomegaly
Référence
Cancers (Basel). 2020 May 31;12(6):